Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 180Lymphoid 166Myeloid 95Plasma cell 94Sarcoma 47CNS 40Classical hematology 39Dermatologic 36Breast 28Genitourinary 25Gynecologic 23Other neoplasm 5Head & Neck 4Other solid neoplasm 3Gastrointestinal 3Thoracic 2Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Peripheral Blood Stem Cell Transplantation × Tumor-Agnostic × Clear all
NCT01525407 2017-08-17

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

Fred Hutchinson Cancer Center

Phase 2 Completed
83 enrolled 16 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡